Amarin Corporation PLC
NASDAQ:AMRN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Amarin Corporation PLC
NASDAQ:AMRN
|
IE |
|
U
|
UBCare Co Ltd
KOSDAQ:032620
|
KR |
|
I
|
Insteel Industries Inc
NYSE:IIIN
|
US |
|
NN Group NV
AEX:NN
|
NL |
|
Tata Power Company Ltd
NSE:TATAPOWER
|
IN |
|
Panca Anugrah Wisesa Tbk PT
IDX:MGLV
|
ID |
|
A
|
Aalberts NV
AEX:AALB
|
NL |
|
Atkinsrealis Group Inc
F:LAV0
|
CA |
|
Tianqi Lithium Corp
SZSE:002466
|
CN |
|
Tohoku Electric Power Co Inc
TSE:9506
|
JP |
Amarin Corporation PLC
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics for cardiovascular disease management. The firm operates through the development and commercialization of Vascepa segment. Its lead product, Vascepa (icosapent ethyl) capsule for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics for cardiovascular disease management. The firm operates through the development and commercialization of Vascepa segment. Its lead product, Vascepa (icosapent ethyl) capsule for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Revenue: Q4 2025 net revenue was $49.2 million, down from $62.3 million in Q4 2024, mainly due to lower U.S. pricing and expected declines in Rest of World sales.
Cost Savings: Amarin achieved a 31% reduction in total operating expenses in Q4 and is halfway to its $70 million restructuring savings target, aiming for full realization by mid-2026.
Cash Flow: The company generated positive cash flow from operations of $7 million in 2025 and ended the year with $303 million in cash and no debt.
European Strategy: Amarin transitioned European commercialization of VAZKEPA to Recordati, bringing a $25 million upfront payment and potential for up to $150 million in future milestones.
U.S. Market Position: VASCEPA maintained market leadership in the U.S. despite generic competition, with all major managed care exclusives retained for 2025.
2026 Outlook: Management expects positive cash flow again in 2026 and sees the year as pivotal, with a focus on further cost efficiencies and international growth.
